Colombia is on the verge of a significant transformation in its medical cannabis market. A new decree will allow the sale of dry cannabis flower locally, creating a booming opportunity for both companies and patients. While initially focusing on smaller producers, the decree prioritizes micro, small and medium-sized enterprises (MIPYMES) based on income, opening the door for many businesses, regardless of size, to enter the market. However, new regulatory hurdles, including the requirement for sanitary authorization for dry flower, will add complexities and delay implementation. This article delves into the impact of this decree, exploring the potential for MIPYMES, the regulatory challenges ahead, and the future of Colombia’s medicinal cannabis landscape.